Stochter
Profile Picture
Global Finance News 01 May 2025, 18:24
Church & Dwight Q1 2025 Financial Summary

Church & Dwight reported mixed first-quarter 2025 results with performance pressured by slowing U.S. consumer demand, retailer destocking, and tariff-related headwinds.

Q1 2025 highlights:
- Net sales declined 2.4% to $1.47 billion (vs. $1.50 billion in Q1 2024)
- Organic sales down 1.2%, with domestic down 3.0%, international up 5.8%, and specialty up 3.2%
- Reported EPS was $0.89; adjusted EPS was $0.91 (down 5.2% year-over-year)
- Operating cash flow was $185.7 million, down from $263.0 million a year earlier

Segment performance:
- Consumer Domestic sales: $1.13 billion, down 3.0% due to inventory reductions and category slowdown
- Consumer International: $261.9 million, up 2.7% on reported basis; 5.8% organic growth
- Specialty Products: $75.4 million, down 9.3% reported but up 3.2% organically

Profitability:
- Adjusted gross margin: 45.1%, down 60 basis points due to higher costs and lower volume
- Adjusted SG&A: 15.2% of sales, up 40 basis points
- Adjusted operating income: $302.5 million (20.6% of sales), down from $312.3 million (20.8%)

Strategic update:
- Company will exit or sell underperforming Flawless, Spinbrush, and Waterpik showerhead brands (total sales ~$150M)
- Expects a Q2 non-cash charge of $60–80 million for impairments and inventory adjustments
- Move expected to reduce tariff exposure by about 80%

2025 full-year outlook (updated):
- Organic sales now expected to grow 0–2% (previously 3–4%)
- Adjusted EPS growth revised to 0–2% (previously 7–8%)
- Adjusted gross margin expected to contract by 60 bps (previously guided to expand by 25 bps)
- Cash from operations expected at $1.05 billion (down from $1.156 billion)
- Capex forecast: $130 million
- Q2 adjusted EPS expected to be $0.85, down 9% year-over-year

New product launches in 2025:
- ARM & HAMMER Power Sheets fragrance-free variant
- Batiste Light dry shampoo
- HERO Mighty Patch Body
- VITAFUSION Power Plus multivitamins

Comments

No comments yet.

Ana sayfa